More than 1 billion people worldwide smoke cigarettes and, according to the World Health Organization, there will still be more than 1 billion in 2025. Some 40 million of them live in the United States. But progress toward the end we all desire—a world in which cigarette smoking is consigned to history—has been painfully slow. These smokers include your neighbors, your friends, maybe even your family. So how, practically, can we help this large population of existing cigarette smokers who’d otherwise continue smoking?

andre_calantzopoulos-1

It’s the burning process that creates the vast majority of the harmful and potentially harmful chemicals that are the primary causes of smoking-related diseases. Science and technology can and must play a role in devising solutions to this problem.

 

André Calantzopoulos
CEO, Philip Morris International

Science and technology can and must play a role in devising solutions to this problem. It’s the burning process that creates the vast majority of the harmful and potentially harmful chemicals that are the primary causes of smoking-related diseases. Our goal is to offer current adult smokers who would otherwise continue smoking non-combustible, or smoke-free, alternatives that have the potential to reduce the risk of developing smoking-related diseases as compared to continued smoking. One such alternative product – IQOS tobacco heating system – is currently under FDA’s regulatory review. The purpose of this site is to inform scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy about this review process and the data behind our application. This site is not for advertising or marketing, and it is not intended for use by consumers.

 

Our vision – for all of us at Philip Morris International – is that these breakthrough products will one day replace cigarettes.

Youth should not use nicotine products. Alongside parents, public health professionals and regulators, makers of tobacco and nicotine products must do their part.
Since 2008, Philip Morris International has invested over $4.5 billion and assembled a team of more than 400 world-class scientists and engineers seeking to develop non-combustible cigarette alternatives.
Our goal is to offer smoke-free alternatives that have the potential to reduce the risk of developing smoking-related diseases as compared to continued smoking.
Given the number of smokers who will continue to smoke cigarettes, it makes sense to offer them less risky alternatives if technology makes it possible, and if such products can be made available.
Four smoke-free product platforms are being developed to offer better alternatives for smokers.
Our product development process follows the principle of “Quality by Design.”
PMI’s toxicological assessment aims to confirm whether the reduced formation of harmful and potentially harmful constituents (HPHCs) leads to reduced toxicity in laboratory models.
Our clinical studies provide human data on the use and acceptance of our smoke-free products as well as their potential to reduce exposure to harmful chemicals and the potential to reduce the risk of smoking-related diseases as compared to continued smoking.
Understanding how our smoke-free products will be perceived and used.
The assessment of our smoke-free products continues after the products are placed on the market.
At each step, rigorous scientific standards are applied to generate data that evaluate whether smoke-free products reduce exposure to harmful and potentially harmful constituents or the risk of developing smoking-related diseases.